The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?

Abstract

Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medications and augmentation strategies has spawned the search for novel treatment approaches. Psychedelic medications used in conjunction with intensive psychotherapy, so-called psychedelic-assisted psychotherapy (PAP), have been evaluated in a limited number of studies as an alternative tactic. This psychedelic renaissance has seen psilocybin, a naturally occurring, potentially hallucinogenic substance occurring in some species of mushrooms, used as one exemplar. The definition of “treatment resistance” varies between different authorities, but there is general agreement that a minimum standard is failure to respond to at least two pharmacological agents from different classes used at a therapeutic dose for an adequate length of time. In the studies to date, more stringent definitions have mostly been applied. Each of the clinical evaluations finds that the addition of a single dose of psilocybin to the psychotherapeutic regimen produces a rapid and clinically significant decline in depressive symptomatology, which is mostly retained in follow-up evaluations out to 12 weeks or longer. Psilocybin was well tolerated with mostly mild to moderate side effects of elevated blood pressure, fatigue, lack of concentration, headache, lethargy, vertigo, feeling of physical or emotional weakness, decreased appetite, nausea, feeling dull, and being easily exhausted, which were transient. Hallucinogen persisting perception disorder (HPPD) has occasionally been reported, while there were few reports of suicidal ideation and behaviour. Psilocybin appears to offer the promise of rapid alleviation of resistant depressive symptoms, but further controlled evaluations are necessary before the drug can be given routinely.

Keywords

Treatment resistant depression / psilocybin / clinical trial / efficacy / adverse events / pharmacokinetics / safety

References

[1] Geiger HA,Wurst MG,Daniels RN.DARK Classics in Chemical Neuroscience: Psilocybin.ACS Chem Neurosci.2018;9:2438-47.

[2] BUSCH AK,JOHNSON WC.L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug.Dis Nerv Syst.1950;11:241-3.

[3] Krebs TS,Johansen PØ.Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.J Psychopharmacol.2012;26:994-1002.

[4] Malhi GS,Parker GB,Crawford J,Wilhelm K,Mitchell PB.Treatment-resistant depression: resistant to definition?Acta Psychiatr Scand.2005;112:302-9.

[5] Burrows GD,Norman TR,Judd FK.Definition and differential diagnosis of treatment-resistant depression.Int Clin Psychopharmacol.1994;9:5-10.

[6] McIntyre RS,Alsuwaidan M,Baune BT,Berk M,Demyttenaere K,Goldberg JF,et al.Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.World Psychiatry.2023;22:394-412.

[7] Thase ME,Rush AJ.When at first you don’t succeed: sequential strategies for antidepressant nonresponders.J Clin Psychiatry.1997;58:23-9.

[8] Fekadu A,Donocik JG,Cleare AJ.Standardisation framework for the Maudsley staging method for treatment resistance in depression.BMC Psychiatry.2018;18:100.

[9] Bartova L,Dold M,Kautzky A,Fabbri C,Spies M,Serretti A,et al.Results of the European Group for the Study of Resistant Depression (GSRD)—basis for further research and clinical practice.World J Biol Psychiatry.2019;20:427-48.

[10] Peeters FPML,Ruhe HG,Wichers M,Abidi L,Kaub K,van der Lande HJ,et al.The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method.J Affect Disord.2016;205:365-71.

[11] Fava M.Diagnosis and definition of treatment-resistant depression.Biol Psychiatry.2003;53:649-59.

[12] Heal DJ,Gosden J,Smith SL.Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.Neuropharmacology.2018;142:89-115.

[13] Hofmann A,Heim R,Brack A,Kobel H.Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim.Experientia.1958;14:107-9. German.

[14] Eivindvik K,Rasmussen KE,Sund RB.Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon.Acta Pharm Nord.1989;1:295-302.

[15] Brown RT,Nicholas CR,Cozzi NV,Gassman MC,Cooper KM,Muller D,et al.Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.Clin Pharmacokinet.2017;56:1543-54.

[16] Kolaczynska KE,Liechti ME,Duthaler U.Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci.2021;1164:122486.

[17] Holze F,Becker AM,Kolaczynska KE,Duthaler U,Liechti ME.Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.Clin Pharmacol Ther.2023;113:822-31.

[18] Hasler F,Bourquin D,Brenneisen R,Bär T,Vollenweider FX.Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.Pharm Acta Helv.1997;72:175-84.

[19] Dodd S,Norman TR,Eyre HA,Stahl SM,Phillips A,Carvalho AF,et al.Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.CNS Spectr.2023;28:416-26.

[20] Hasler F,Bourquin D,Brenneisen R,Vollenweider FX.Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man.J Pharm Biomed Anal.2002;30:331-9.

[21] Lindenblatt H,Krämer E,Holzmann-Erens P,Gouzoulis-Mayfrank E,Kovar KA.Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction.J Chromatogr B Biomed Sci Appl.1998;709:255-63.

[22] Kalberer F,Kreis W,Rutschmann J.The fate of psilocin in the rat.Biochem Pharmacol.1962;11:261-9.

[23] Dinis-Oliveira RJ.Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.Drug Metab Rev.2017;49:84-91.

[24] Glennon RA,Titeler M,McKenney JD.Evidence for 5-HT₂ involvement in the mechanism of action of hallucinogenic agents.Life Sci.1984;35:2505-11.

[25] Vollenweider FX,Vollenweider-Scherpenhuyzen MF,Bäbler A,Vogel H,Hell D.Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.Neuroreport.1998;9:3897-902.

[26] Ling S,Ceban F,Lui LMW,Lee Y,Teopiz KM,Rodrigues NB,et al.Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.CNS Drugs.2022;36:17-30.

[27] López-Giménez JF,González-Maeso J.Hallucinogens and Serotonin 5-HT_2A Receptor-Mediated Signaling Pathways. In: Halberstadt AL,Vollenweider FX,Nichols DE. editors.Behavioral Neurobiology of Psychedelic Drugs.Berlin, Heidelberg:Springer Berlin Heidelberg2018.pp. 45–73.

[28] Wallach J,Cao AB,Calkins MM,Heim AJ,Lanham JK,Bonniwell EM,et al.Identification of 5-HT_2A receptor signaling pathways associated with psychedelic potential.Nat Commun.2023;14:8221.

[29] Duclot F,Kabbaj M.The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders.Front Behav Neurosci.2017;11:35.

[30] Shao LX,Liao C,Gregg I,Davoudian PA,Savalia NK,Delagarza K,et al.Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.Neuron.2021;109:2535-44.e4.

[31] Ly C,Greb AC,Cameron LP,Wong JM,Barragan EV,Wilson PC,et al.Psychedelics Promote Structural and Functional Neural Plasticity.Cell Rep.2018;23:3170-82.

[32] Castrén E,Antila H.Neuronal plasticity and neurotrophic factors in drug responses.Mol Psychiatry.2017;22:1085-95.

[33] Gattuso JJ,Perkins D,Ruffell S,Lawrence AJ,Hoyer D,Jacobson LH,et al.Default Mode Network Modulation by Psychedelics: A Systematic Review.Int J Neuropsychopharmacol.2023;26:155-88.

[34] LEARY T,LITWIN GH,METZNER R.REACTIONS TO PSILOCYBIN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT.J Nerv Ment Dis.1963;137:561-73.

[35] Holze F,Ley L,Müller F,Becker AM,Straumann I,Vizeli P,et al.Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology.2022;47:1180-7.

[36] Hasler F,Grimberg U,Benz MA,Huber T,Vollenweider FX.Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.Psychopharmacology (Berl).2004;172:145-56.

[37] Sabé M,Sulstarova A,Glangetas A,De Pieri M,Mallet L,Curtis L,et al.Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Mol Psychiatry.2025;30:1223-55.

[38] Isbell H,Wolbach AB,Wikler A,Miner EJ.Cross tolerance between LSD and psilocybin.Psychopharmacologia.1961;2:147-59.

[39] Johnson MW,Griffiths RR,Hendricks PS,Henningfield JE.The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.Neuropharmacology.2018;142:143-66.

[40] Johnson M,Richards W,Griffiths R.Human hallucinogen research: guidelines for safety.J Psychopharmacol.2008;22:603-20.

[41] Yerubandi A,Thomas JE,Bhuiya NMMA,Harrington C,Villa Zapata L,Caballero J.Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.JAMA Netw Open.2024;7:e245960.

[42] Hinkle JT,Graziosi M,Nayak SM,Yaden DB.Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.JAMA Psychiatry.2024;81:1225-35.

[43] Gable RS.Comparison of acute lethal toxicity of commonly abused psychoactive substances.Addiction.2004;99:686-96.

[44] Goodwin GM,Malievskaia E,Fonzo GA,Nemeroff CB.Must Psilocybin Always “Assist Psychotherapy”?Am J Psychiatry.2024;181:20-5.

[45] Goodwin GM,Aaronson ST,Alvarez O,Arden PC,Baker A,Bennett JC,et al.Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.N Engl J Med.2022;387:1637-48.

[46] Alpert MD,O’Donnell KC,Paleos CA,Sola E,Stauffer CS,Wagner AC,et al.Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.Am J Psychiatry.2024;181:76-7.

[47] Yaden DB,Griffiths RR.The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects.ACS Pharmacol Transl Sci.2021;4:568-72.

[48] Aday JS,Horton D,Fernandes-Osterhold G,O’Donovan A,Bradley ER,Rosen RC,et al.Psychedelic-assisted psychotherapy: where is the psychotherapy research?Psychopharmacology (Berl).2024;241:1517-26.

[49] Kirlić N,Lennard-Jones M,Atli M,Malievskaia E,Modlin NL,Peck SK,et al.Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.Am J Psychiatry.2025;182:126-32.

[50] Griffiths RR,Johnson MW,Carducci MA,Umbricht A,Richards WA,Richards BD,et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.J Psychopharmacol.2016;30:1181-97.

[51] Ross S,Bossis A,Guss J,Agin-Liebes G,Malone T,Cohen B,et al.Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.J Psychopharmacol.2016;30:1165-80.

[52] Grob CS,Danforth AL,Chopra GS,Hagerty M,McKay CR,Halberstadt AL,et al.Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.Arch Gen Psychiatry.2011;68:71-8.

[53] Schipper S,Nigam K,Schmid Y,Piechotta V,Ljuslin M,Beaussant Y,et al.Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.Cochrane Database Syst Rev.2024:CD015383.

[54] Davis AK,Barrett FS,May DG,Cosimano MP,Sepeda ND,Johnson MW,et al.Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.JAMA Psychiatry.2021;78:481-9.

[55] Perez N,Langlest F,Mallet L,De Pieri M,Sentissi O,Thorens G,et al.Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.Eur Neuropsychopharmacol.2023;76:61-76.

[56] Sloshower J,Skosnik PD,Safi-Aghdam H,Pathania S,Syed S,Pittman B,et al.Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.J Psychopharmacol.2023;37:698-706.

[57] Carhart-Harris RL,Bolstridge M,Rucker J,Day CM,Erritzoe D,Kaelen M,et al.Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.Lancet Psychiatry.2016;3:619-27.

[58] Carhart-Harris RL,Bolstridge M,Day CMJ,Rucker J,Watts R,Erritzoe DE,et al.Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.Psychopharmacology (Berl).2018;235:399-408.

[59] Goodwin GM,Aaronson ST,Alvarez O,Atli M,Bennett JC,Croal M,et al.Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.J Affect Disord.2023;327:120-7.

[60] Goodwin GM,Croal M,Feifel D,Kelly JR,Marwood L,Mistry S,et al.Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.Neuropsychopharmacology.2023;48:1492-9.

[61] Aaronson ST,van der Vaart A,Miller T,LaPratt J,Swartz K,Shoultz A,et al.Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.Am J Psychiatry.2025;182:104-13.

[62] Ellis S,Bostian C,Feng W,Fischer E,Schwartz G,Eisen K,et al.Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study.J Affect Disord.2025;369:381-9.

[63] Rosenblat JD,Meshkat S,Doyle Z,Kaczmarek E,Brudner RM,Kratiuk K,et al.Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med.2024;5:190-200.e5.

[64] Aaronson ST,van der Vaart A,Miller T,LaPratt J,Swartz K,Shoultz A,et al.Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.JAMA Psychiatry.2024;81:555-62.

[65] Nichols DE.Psychedelics.Pharmacol Rev.2016;68:264-355.

[66] Hermle L,Ruchsow M,Täschner KL.Hallucinogen Persisting Perception Disorder (HPPD) and Flashback Phenomena – Differential Diagnosis and Explanation Models.Fortschr Neurol Psychiatr.2015;83:506-15. German.

[67] Espiard ML,Lecardeur L,Abadie P,Halbecq I,Dollfus S.Hallucinogen persisting perception disorder after psilocybin consumption: a case study.Eur Psychiatry.2005;20:458-60.

[68] Skryabin VY,Vinnikova M,Nenastieva A,Alekseyuk V.Hallucinogen persisting perception disorder: A literature review and three case reports.J Addict Dis.2018;37:268-78.

[69] Martinotti G,Santacroce R,Pettorruso M,Montemitro C,Spano MC,Lorusso M,et al.Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.Brain Sci.2018;8:47.

[70] Stahl SM.Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications5th ed. Cambridge University Press; 2021.

[71] Abraham HD.Visual phenomenology of the LSD flashback.Arch Gen Psychiatry.1983;40:884-9.

[72] Halpern JH,Lerner AG,Passie T.A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. In: Halberstadt AL,Vollenweider FX,Nichols DE. editors.Behavioral Neurobiology of Psychedelic Drugs.Berlin, Heidelberg:Springer Berlin Heidelberg2018.pp. 333–60.

[73] Holland D,Passie T.Flashback-Phänomene als Nachwirkung von Halluzinogeneinnahme: Eine kritische Untersuchung zu klinischen und ätiologischen Aspekten1st ed. VWB-Verlag; 2011.

[74] Romeo B,Kervadec E,Fauvel B,Strika-Bruneau L,Amirouche A,Verroust V,et al.Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.Psychiatry Res.2024;335:115880.

[75] Yao Y,Guo D,Lu TS,Liu FL,Huang SH,Diao MQ,et al.Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.Psychiatry Res.2024;335:115886.

[76] Freitas RR,Gotsis ES,Gallo AT,Fitzgibbon BM,Bailey NW,Fitzgerald PB.The safety of psilocybin-assisted psychotherapy: A systematic review.Aust N Z J Psychiatry.2025;59:128-51.

[77] Hodge AT,Sukpraprut-Braaten S,Narlesky M,Strayhan RC.The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.J Psychoactive Drugs.2023;55:40-50.

[78] Straumann I,Holze F,Becker AM,Ley L,Halter N,Liechti ME.Safety pharmacology of acute psilocybin administration in healthy participants.Neurosci Appl.2024;3:104060.

[79] Wsół A.Cardiovascular safety of psychedelic medicine: current status and future directions.Pharmacol Rep.2023;75:1362-80.

[80] Eisner B.Set, setting, and matrix.J Psychoactive Drugs.1997;29:213-6.

[81] Villiger D.Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?Int Rev Psychiatry.2024;36:869-78.

[82] Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists [Internet]Commonwealth of Australia; [cited 2025 Jun 26]. Available from: https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists

[83] Luoma JB,Chwyl C,Bathje GJ,Davis AK,Lancelotta R.A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.J Psychoactive Drugs.2020;52:289-99.

[84] Wen A,Singhal N,Jones BDM,Zeifman RJ,Mehta S,Shenasa MA,et al.A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.Psychedelic Med (New Rochelle).2024;2:15-24.

[85] Husain MI,Blumberger DM,Castle DJ,Ledwos N,Fellows E,Jones BDM,et al.Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.BJPsych Open.2023;9:e134.

[86] Hesselgrave N,Troppoli TA,Wulff AB,Cole AB,Thompson SM.Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.Proc Natl Acad Sci U S A.2021;118:e2022489118.